- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03149432
Effectiveness of Mirror Therapy in Patients With Amputations of Lower Limbs of Vascular Origin (MIR-PHAN)
Study Overview
Status
Intervention / Treatment
Detailed Description
Several variables at the beginning collected to study the predictive factors of effectiveness of mirror therapy:
- Age
- Sex
- Delay from amputation
- Etiology: neuropathy associated or not
- VAS of preoperative pain
- VAS phantom pain at baseline
- Localization of pain
- Ability to mobilize the phantom limb
- Healing obtained or not
- Type of stump: defective or not
- Type of amputation
- Circumstance of amputation: programmed / not programmed
- Psychological experience: Montgomery and Asberg Depression Scale score (MADRS)
- Socio-economic level
- The initial analgesic neuropathic treatment
- Possible previous prosthesis
It was also collected at week 4 and 8 :
- The level of advancement of the equipment by prosthesis
Each patient with the inclusion criteria, who agreed to participate in the study after reading the information note and signed consent, will be included in one of the two groups after randomization.
Group Reference Analgesic: receiving a reference antalgic management according to the protocol of the service: traditional management and treatment with Gabapentin.
Group Reference Analgesic and mirror therapy: receiving the reference antalgic management according to the protocol of the service: traditional management and treatment with Gabapentin as well as a management by mirror therapy during the first 4 weeks.
In group Reference analgesic and Mirror therapy, the mirror therapy will be performed by a physiotherapist trained in practice and already applying this technique in the center. Each patient receives, during the first week of treatment, 5 sessions of 20 minutes each decomposed as follows: 15 minutes of motor exercise and 5 minutes of sensory exercise. The content of the session was decided and put in place by the physiotherapist.
During the following 3 weeks the patients must practice self-rehabilitation at the rate of 5 sessions per week with a weekly re-evaluation session by the physiotherapist.
Before inclusion, the patient should be weaned as far as possible from neuropathic neuropathic treatments other than Gabapentin introduced for the treatment of phantom pain.
In both groups, patients receive the reference treatment according to the protocol of the service: titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks.
Thereafter, depending on the patient's response and tolerance, the dose may be increased in increments of 300 mg / day every 2-3 days to a maximum dose of 3600 mg / day. A slower titration of gabapentin may be appropriate in some patients. The minimum time to reach a dose of 1800 mg / day is one week, to reach 2400 mg / day it is 2 weeks in total and to reach 3600 mg / day it is 3 weeks in total.
No other analgesic neuropathic treatment could be introduced or increased (PREGABALINE, AMITRIPTYLINE, DULOXETINE, MORPHINIC).
A punctual treatment (PARACETAMOL, CODEINE, NSAID, NEFOPAM) on acute pain without action on neuropathic type pain, linked to a different pathology is allowed.
If in Reference Analgesic group, the phantom limb pain was not sufficiently relieved at the end of the protocol, and the mirror therapy seems to be effective, a treatment by mirror therapy can be proposed to them.
The VAS and the details of the analgesic treatment will be collected every 2 weeks, blinded by an independent evaluator. Patients should not tell the evaluator which group they are assigned to.
The advancement of the prosthesis were collected at 4 and 8 weeks. Moreover, this is an observational study, following routine procedures already practiced systematically in the institution with this patient population. There are no additional procedures for diagnosis or additional medical supervision in this study.
16 subjects per group make it possible to demonstrate a size 1 effect with a risk of first species of 5% and a power of 80%. In order to take into account the risk of exiting the trial, we plan to include 20 patients in each group, sp a total of 40 patients.
Statistical analysis will use Sigma Plot® 12.5 for Windows Systat Software, Inc. or R software. Quantitative data will be reported in terms of mean, standard deviation and / or median and interquartile range. Qualitative data will be reported in terms of numbers and percentages.
The groups will be compared by Chi2 tests, or Fisher tests in case of insufficient numbers, for the qualitative variables. For quantitative variables the groups will be compared by T tests, or Wilcoxon tests if the variables do not have a normal distribution.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Valenton, France, 94460
- Institut Merle d'Aubigné
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient over 18 years of age who signed the memorandum.
- Patient hospitalized in the service for setting up equipment.
- In the aftermath of a major amputation of the lower limb, of vascular origin.
- Patients with phantom pain greater than or equal to 30 Visual Analog Evaluation (EVA); Whether pharmacologically or not.
Exclusion Criteria:
- Refusal to participate in the study.
- Presence of cognitive or psychiatric disorders that compromise the realization of mirror therapy.
- Presence of neurological, rheumatological or orthopedic disorders that may prevent movement of the unaffected limb.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Reference analgesic
Gabapentin Rehabilitation Local care
|
titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
local care for directed healing of the stump.
|
EXPERIMENTAL: reference analgesic and mirror therapy
Mirror Therapy Gabapentin Rehabilitation Local care
|
titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
local care for directed healing of the stump.
by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of the phantom limb pain using a VAS
Time Frame: 4 weeks
|
The EVA and the details of the analgesic treatment were collected every two weeks, blinded by an independent evaluator.
Patients should not tell the evaluator which group they are assigned to.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of the Frequency of phantom limb pain episodes
Time Frame: every 2 weeks from day inclusion to Week 8
|
Frequencies of painful attacks were collected every two weeks, blinded by an independent evaluator.
Patients should not tell the evaluator which group they are assigned to.
|
every 2 weeks from day inclusion to Week 8
|
change from baseline of the duration of phantom limb pain episodes.
Time Frame: every 2 weeks from day inclusion to Week 8
|
Duration of painful attacks were collected every two weeks, blinded by an independent evaluator.
Patients should not tell the evaluator which group they are assigned to.
|
every 2 weeks from day inclusion to Week 8
|
Change from baseline of the consumption of pharmacological analgesic drugs
Time Frame: every 2 weeks from day inclusion to Week 8
|
The consumption of pharmacological analgesic drugs were collected every two weeks, blinded by an independent evaluator.
Patients should not tell the evaluator which group they are assigned to.
|
every 2 weeks from day inclusion to Week 8
|
Quality of life? MEASUREMENT OF PAIN SENSATION
Time Frame: every 2 weeks from day inclusion to Week 8
|
SF12
|
every 2 weeks from day inclusion to Week 8
|
Sleep disorders
Time Frame: every 2 weeks from day inclusion to Week 8
|
Spiegel Questionnaire
|
every 2 weeks from day inclusion to Week 8
|
Collaborators and Investigators
Investigators
- Principal Investigator: Larlène Lacout, MD, APHP
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Perceptual Disorders
- Pain, Postoperative
- Phantom Limb
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- Anticonvulsants
- Antimanic Agents
- Gabapentin
Other Study ID Numbers
- 2016-A00771-50
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amputation
-
Liberating Technologies, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedAmputation | Prosthesis User | Amputation; Traumatic, Hand | Amputation, CongenitalUnited States
-
Shirley Ryan AbilityLabEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingAmputation | Amputation; Traumatic, Limb | Upper Limb Amputation at the Hand | Upper Limb Amputation at the WristUnited States
-
Medipol UniversityRecruitingEvaluation of Functionality of Amputees According to the Medicare Functional K Classification SystemAmputation | Amputation; Traumatic, Leg, LowerTurkey
-
Boninger, Michael, MDNational Institute of Neurological Disorders and Stroke (NINDS); Ripple Therapeutics...RecruitingAmputation | Amputation; Traumatic, HandUnited States
-
Fondazione Don Carlo Gnocchi OnlusCompletedAmputation | Amputation; Traumatic, Leg, LowerItaly
-
Fondazione Don Carlo Gnocchi OnlusCompletedAmputation | Amputation; Traumatic, Leg, LowerItaly
-
Hacettepe UniversityCompleted
-
University of MichiganActive, not recruitingAmputation | Amputation; Traumatic, Leg, LowerUnited States
-
Shirley Ryan AbilityLabUnited States Department of DefenseCompletedAmputation | Amputation; Traumatic, Arm, UpperUnited States
-
Liberating Technologies, Inc.Vivonics, Inc.CompletedLower Limb Amputation Below Knee (Injury) | Amputation | Prosthesis User | Amputation; Traumatic, Leg, Lower | Limb; Absence, Congenital, Lower | Amputation StumpUnited States
Clinical Trials on Gabapentin
-
University Hospital, GhentAmsterdam UMC, location VUmc; University GhentCompletedEpilepsy and Neuropathic PainBelgium
-
Samuel Lunenfeld Research Institute, Mount Sinai...Completed
-
Mayo ClinicCompleted
-
Viatris Specialty LLCCompletedAbuse PotentialUnited States
-
University of KarachiCenter for Bioequivalence Studies and Clinical Research; Merck Pvt. Ltd, PakistanCompletedHealthy Volunteers | Bioequivalence StudyPakistan
-
Indiana UniversityCompletedPostoperative PainUnited States
-
Celgene CorporationCompletedBreast Neoplasms | Metastases, NeoplasmUnited States
-
Celgene CorporationCompletedNeoplasms | Metastases, NeoplasmUnited States
-
XenoPort, Inc.Completed
-
Endo PharmaceuticalsCompletedCarpal Tunnel Syndrome | Complex Regional Pain Syndrome | Peripheral Neuropathy | Diabetic Neuropathy | Postherpetic Neuralgia | HIV Neuropathy | Idiopathic Sensory NeuropathyUnited States